Hwail Pharmaceutical Co.Ltd Asset Resilience Ratio
Hwail Pharmaceutical Co.Ltd asset resilience ratio. Hwail Pharmaceutical Co.Ltd (061250) has an Asset Resilience Ratio of 8.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Hwail Pharmaceutical Co.Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hwail Pharmaceutical Co.Ltd (2011–2024)
Asset resilience ratio of Hwail Pharmaceutical Co.Ltd from 2011 to 2024. This chart shows how Hwail Pharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. Read debt load of Hwail Pharmaceutical Co.Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hwail Pharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 061250 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩18.50 Billion | 8.68% |
| Total Liquid Assets | ₩18.50 Billion | 8.68% |
Asset Resilience Insights
- Limited Liquidity: Hwail Pharmaceutical Co.Ltd maintains only 8.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hwail Pharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Hwail Pharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Hwail Pharmaceutical Co.Ltd Asset Resilience Ratio by Year (2011–2024)
Hwail Pharmaceutical Co.Ltd asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Hwail Pharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 33.51% | ₩72.26 Billion ≈ $48.97 Million |
₩215.61 Billion ≈ $146.12 Million |
-5.11pp |
| 2023-12-31 | 38.63% | ₩71.84 Billion ≈ $48.69 Million |
₩186.00 Billion ≈ $126.05 Million |
-1.97pp |
| 2022-12-31 | 40.60% | ₩75.35 Billion ≈ $51.06 Million |
₩185.60 Billion ≈ $125.78 Million |
-5.35pp |
| 2021-12-31 | 45.94% | ₩89.20 Billion ≈ $60.45 Million |
₩194.15 Billion ≈ $131.57 Million |
+23.73pp |
| 2020-12-31 | 22.21% | ₩37.69 Billion ≈ $25.54 Million |
₩169.68 Billion ≈ $114.99 Million |
-0.60pp |
| 2019-12-31 | 22.81% | ₩31.80 Billion ≈ $21.55 Million |
₩139.40 Billion ≈ $94.47 Million |
+8.72pp |
| 2018-12-31 | 14.09% | ₩17.39 Billion ≈ $11.78 Million |
₩123.41 Billion ≈ $83.63 Million |
-0.61pp |
| 2017-12-31 | 14.70% | ₩18.22 Billion ≈ $12.35 Million |
₩123.90 Billion ≈ $83.97 Million |
+7.00pp |
| 2016-12-31 | 7.70% | ₩9.91 Billion ≈ $6.71 Million |
₩128.62 Billion ≈ $87.16 Million |
+6.29pp |
| 2015-12-31 | 1.42% | ₩1.99 Billion ≈ $1.35 Million |
₩140.27 Billion ≈ $95.06 Million |
-2.61pp |
| 2014-12-31 | 4.03% | ₩4.95 Billion ≈ $3.36 Million |
₩122.92 Billion ≈ $83.30 Million |
+2.44pp |
| 2013-12-31 | 1.58% | ₩1.95 Billion ≈ $1.32 Million |
₩123.02 Billion ≈ $83.37 Million |
-1.66pp |
| 2012-12-31 | 3.24% | ₩3.67 Billion ≈ $2.49 Million |
₩113.14 Billion ≈ $76.67 Million |
-4.67pp |
| 2011-12-31 | 7.91% | ₩7.81 Billion ≈ $5.30 Million |
₩98.73 Billion ≈ $66.91 Million |
-- |
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.